Methods of treating heart failure using an anti-GM-CSF antibody
View Patent ↗This invention relates to methods of treating a patient suffering from heart failure, or a patient at risk for heart failure, using a GM-CSF antagonist.
1. A method for treating a patient that has heart failure, the method comprising administering a therapeutically effective amount of a granulocyte macrophage colony stimulating factor (GM-CSF) antagonist to the patient, wherein the antagonist is an anti-GM-CSF antibody.
2. The method of claim 1 , wherein the patient has a left ventricular ejection fraction of 40% or less.
3. The method of claim 1 , wherein the patient has Class II, Class III, or Class IV heart failure as determined with reference to the New York Heart Association classification.
4. The method of claim 1 , wherein the patient is being treated with an angiotensin-converting enzyme (ACE) inhibitor.
5. The method of claim 1 , wherein the anti-GM-CSF antibody is a monoclonal antibody.
6. The method of claim 1 , wherein the anti-GM-CSF antibody is a nanobody or a camelid antibody.
7. The method of claim 1 , wherein the anti-GM-CSF antibody is an antibody fragment that is a Fab, a Fab′, a F(ab′) 2 , a scFv, or a dAB.
8. The method of claim 7 , wherein the antibody fragment is conjugated to polyethylene glycol.
9. The method of claim 1 , wherein the anti-GM-CSF antibody has an affinity of about 100 pM to about 10 nM.
10. The method of claim 1 , wherein the anti-GM-CSF antibody has an affinity of about 0.5 pM to about 100 pM.
11. The method of claim 1 , wherein the anti-GM-CSF antibody is a neutralizing antibody.
12. The method of claim 1 , wherein the anti-GM-CSF antibody is a recombinant or chimeric antibody.
13. The method of claim 1 , wherein the anti-GM-CSF antibody comprises a human variable region.
14. The method of claim 13 , wherein the anti-GM-CSF antibody comprises a human light chain constant region.
15. The method of claim 13 , wherein the anti-GM-CSF antibody comprises a human heavy chain constant region.
16. The method of claim 15 , wherein the human heavy chain constant region is a gamma chain.
17. The method of claim 1 , wherein the anti-GM-CSF antibody binds to the same epitope as chimeric 19/2.
18. The method of claim 17 , wherein the anti-GM-CSF antibody comprises the V H and V L regions of chimeric 19/2.
19. The method of claim 18 , wherein the anti-GM-CSF antibody comprises a human heavy chain constant region.
20. The method of claim 19 , wherein the human heavy chain constant region is a gamma region.
21. The method of claim 17 , wherein the anti-GM-CSF antibody comprises the V H region and V L region CDR1, CDR2, and CDR3 of chimeric 19/2.
22. The method of claim 1 , wherein the anti-GM-CSF antibody is a human antibody.
23. The method of claim 1 , wherein the anti-GM-CSF antibody has a half-life of about 7 to about 25 days.
24. The method of claim 1 , wherein the anti-GM-CSF antibody is administered at a dose between about 1 mg/kg of body weight and about 10 mg/kg of body weight.
25. The method of claim 1 , wherein the anti-GM-CSF antibody is administered intravenously.
26. The method of claim 1 , wherein the anti-GM-CSF antibody is administered subcutaneously.
27. The method of claim 1 , wherein the anti-GM-CSF antibody is administered intramuscularly.
28. The method of claim 1 , wherein the anti-GM-CSF antibody is administered multiple times.